Table 2 Breast Cancer University Hospitals (UH) population (2005–2022) description and comparison stratified by race in treatment patterns. IQR = interquartile range.

Surgery—n (%)

1819 (58%)

7167 (50.1%)

 < 0.001

 Mastectomy—n (%)

490 (15.6%)

1790 (12.5%)

 < 0.001

 Lumpectomy—n (%)

583 (18.6%)

1771 (12.4%)

 < 0.001

 Time to surgery (days)—median (IQR)

42 (27–106)

34 (21–62)

 < 0.001

Radiotherapy (R)—n (%)

1320 (42.1%)

4015 (28%)

 < 0.001

 Right side only radiotherapy—n (%)

371 (11.8%)

1136 (7.9%)

 < 0.001

 Left side only radiotherapy—n (%)

315 (10%)

967 (6.8%)

 < 0.001

 Time to radiotherapy (days)—median (IQR)

204 (99–287)

138 (77–253)

 < 0.001

Chemotherapy (C)—n (%)

1085 (34.6%)

3528 (24.6%)

 < 0.001

 Time to chemotherapy (days)—median (IQR)

70 (37–112)

62 (36–95)

 < 0.001

Hormone therapy (H)—n (%)

1335 (42.6%)

5853 (40.9%)

0.08

 Time to hormone therapy (days)—median (IQR)

138 (72–245)

126 (72–218)

0.003

Immunotherapy (I)—n (%)

129 (4.1%)

406 (2.8%)

 < 0.001

 Time to immunotherapy (days)—median (IQR)

68 (43–127)

59 (34–128)

0.44

Combined therapy

 C + R − n (%)

718 (22.9%)

1,558 (10.9%)

 < 0.001

 I + R − n (%)

87 (2.8%)

206 (1.4%)

 < 0.001

 H + R − n (%)

733 (23.4%)

2,285 (16%)

 < 0.001

 H + C + R − n (%)

383 (12.2%)

1,008 (7%)

 < 0.001

 H + C + R + I − n (%)

39 (1.2%)

111 (0.8%)

0.01

Agents

 Anthracyclines—n (%)

357 (11.4%)

1,053 (7.4%)

 < 0.001

 Non-anthracycline cytotoxic chemotherapy—n (%)

694 (22.1%)

2,214 (15.5%)

 < 0.001

 PIK3CA/mTOR inhibitors—n (%)

4 (0.1%)

9 (0.1%)

0.4

 Aromatase inhibitors—n (%)

375 (12%)

1,098 (7.7%)

 < 0.001

 LHRH agonists—n (%)

82 (2.6%)

270 (1.9%)

0.01

 ER antagonists—n (%)

196 (6.2%)

631 (4.4%)

 < 0.001

 Newer therapies—n (%)

211 (6.7%)

752 (5.3%)

 < 0.001

Appointments per patient—median (IQR)

10 (5–23)

8 (4–17)

 < 0.001

% of appointments attended—median (IQR)

66 (44–80)

69 (50–85)

 < 0.001